论文部分内容阅读
目的评价瑞舒伐他汀与普罗布考联用对急性冠状动脉综合征(ACS)患者超敏C反应蛋白及血脂水平的影响。方法 65例急性冠状动脉综合征患者随机分为3组:瑞舒伐他汀组(10 mg.d-1),普罗布考组(0.5 g,bid)和瑞舒伐他汀(10 mg.d-1)与普罗布考(0.5 g,bid)联合治疗组。于治疗前及治疗第8周后,分别测定血清超敏C反应蛋白(hs-CRP)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平。结果治疗8周后与治疗前比较,3个治疗组的血清hs-CRP、TC、LDL-C水平均明显降低;与单用组比较联合治疗组差异有统计学意义(P<0.05或P<0.01)。结论瑞舒伐他汀与普罗布考联用治疗ACS,能更有效地降低血清hs-CRP和血脂水平。
Objective To evaluate the effect of rosuvastatin and probucol on the levels of high-sensitivity C-reactive protein and lipids in patients with acute coronary syndrome (ACS). Methods 65 patients with acute coronary syndrome were randomly divided into 3 groups: rosuvastatin group (10 mg.d-1), probucol group (0.5 g bid) and rosuvastatin (10 mg.d- 1) and probucol (0.5 g, bid) combined treatment group. The levels of serum hs-CRP, TC, TG, LDL-C and high-density lipoprotein cholesterol Lipoprotein cholesterol (HDL-C) levels. Results After 8 weeks of treatment, the levels of hs-CRP, TC and LDL-C in the three treatment groups were significantly decreased compared with those before treatment. The difference was statistically significant (P <0.05 or P < 0.01). Conclusions Rosuvastatin and probucol combined with ACS can effectively reduce serum hs-CRP and blood lipid levels.